Recent Insider Activity: Acura Pharmaceuticals, Inc. $ACUR

11b289f1c9f1bb35910d0bd2505737fd

Acura Pharmaceuticals, Inc. (ACUR) insider have most recently took part in a trading activity. On Aug 29, 2017 Brzeczko Albert W, VP Technical Affairs – APT bought 10,800 shares having total worth of $5,076 at the price of $0.47 per share, following the transaction a total of 16,000 shares owned by Brzeczko Albert W.

Shares of Acura Pharmaceuticals, Inc. (ACUR) traded up 4.65% on Aug 28, 2017, hitting $0.45. 6,411 shares of the company’s stock traded hands. Acura Pharmaceuticals, Inc. has a 52 week low of $0.42 and a 52 week high of $3.44. The company’s market cap is $19 million.

Acura Pharmaceuticals, Inc. (ACUR) last announced its earnings results on Aug 14, 2017. The company reported -0.18 earnings per share (EPS) for the quarter. The company had revenue of $0 million for the quarter, compared to the consensus estimate of $0 million. During the same quarter in the previous year, the company posted -0.28 earnings per share. The company’s revenue for the quarter was down 64% on a year-over-year basis.

2017-08-14 2016-11-14 2016-05-02 2016-02-29 2015-11-04 2015-08-03 2015-05-04 2015-03-02 2014-08-04 2014-05-05
earnings per share -0.18 -0.19 -0.28 -0.08 -0.23 -0.05 0.03 -0.06 -0.07 -0.08
Revenue(M) 0.09 0.22 0.22 2.68 0.21 0.34 5.36 0.03 0.04 0.04

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary Aversion and Impede Technologies. Its products and product candidates are based on widely-used commercial products and do not alter the safety and efficacy of the active pharmaceutical ingredients. Its product, Oxecta, or Oxecta (formerly Acurox), was approved for marketing by the United States Food and Drug Administration, or FDA, on June 17, 2011. Oxecta represents the first immediate-release oxycodone product approved by the FDA that applies to its Aversion Technology. Aversion is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering associated with abuse. Oxecta will be manufactured and commercialized by Pfizer under its October 2007 license agreement with a subsidiary of Pfizer. In addition to Oxecta, it has licensed to Pfizer the rights to develop, manufacture and commercialize three other immediate-release opioid products utilizing Aversion Technology in the United States, Canada and Mexico, including: hydrocodone bitartrate /acetaminophen tablets; oxycodone HCl / acetaminophen tablets; and an undisclosed opioid analgesic tablet product. Such potential competitors include, but may not be limited to, Pain Therapeutics, in collaboration with Pfizer, Purdue Pharma, Atlantic Pharmaceuticals, Egalet a/s, KemPharm and Collegium Pharmaceuticals, Inc. The company is subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic Act, or the FD&C Act, and, to a lesser extent, by state and local governments. The company’s portfolio of product candidates includes opioid analgesics intended to effectively relieve pain while simultaneously discouraging common methods of pharmaceutical product misuse and abuse including: intravenous injection of dissolved tablets or capsules, nasal snorting of crushed tablets or capsules, and intentional swallowing of excess quantities of tablets or capsules.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.